ARIAD PHARMACEUTICALS INC (ARIA) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

View amendments to this 10-K report filed on 4/29/2016
PDFPDF Microsoft WordWord Microsoft ExcelExcel SubscribeRSS E-mailEmail Smartphone and TabletMobile last10k.com/sec-filings/aria/0001193125-16-485544.htm

Exhibit 99.1

ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress

Iclusig Net Product Revenue Guidance for 2016 in the Range of $190 Million to $200 Million

Filing for U.S. Marketing Approval of Brigatinib Expected This Year

Conference Call Scheduled Today at 8:30 a.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 23, 2016--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2015 and issued 2016 product revenue guidance. Additionally, the Company provided an update on corporate developments and key objectives for 2016.

”We had a strong fourth quarter of sales for Iclusig and 102 percent growth year over year,” stated Paris Panayiotopoulos, president and chief executive officer of ARIAD. “This is a very important year for ARIAD as we work to complete our ongoing review of strategic initiatives to deliver patient and shareholder value. In addition to maximizing top-line growth of Iclusig, a key event this year will be the presentation of pivotal, registration data on brigatinib at ASCO, along with our planned filing for marketing approval of brigatinib in the U.S.”

2015 Fourth Quarter and Full-Year Financial Results

Revenues

  • Net product revenues from sales of Iclusig were $33.3 million for the fourth quarter of 2015, an increase of 56% from the fourth quarter of 2014.
    • U.S. sales of Iclusig were $25.1 million for the fourth quarter, an increase of 48% from the fourth quarter of 2014.
    • European sales of Iclusig were $8.2 million for the fourth quarter, an increase of 86% from the fourth quarter of 2014.
  • Net product revenues from sales of Iclusig for the year ended December 31, 2015 were $112.5 million, an increase of 102% from 2014. In the U.S., net product revenue totaled $85.7 million in 2015, an increase of 114% from 2014, while in the EU, net product revenue totaled $26.8 million in 2015, an increase of 71% from 2014.

The following information was filed by ARIAD PHARMACEUTICALS INC on Tuesday, February 23, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

 Please wait while we load the requested 10-K Annual Report. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643d10k.htm

Companies may provide additional information to their SEC Filings as exhibits. Click a link below to view an exhibit that was filed with this report:

Exhibit 4.1 - INSTRUMENTS DEFINING THE RIGHTS OF SECURITY HOLDERS, INCLUDING INDENTURES

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643dex41.htm
Exhibit 21.1 - SUBSIDARIES OF THE REGISTRANT

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643dex211.htm
Exhibit 23.1 - CONSENTS OF EXPERTS AND COUNSEL

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643dex231.htm
Exhibit 31.1 - RULE 13A-14(A)/15D-14(A) CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643dex311.htm
Exhibit 31.2 - RULE 13A-14(A)/15D-14(A) CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643dex312.htm
Exhibit 32.1 - SECTION 1350 CERTIFICATION

 Please wait while we load the requested exhibit. If it does not load, please click the link below:

 https://www.last10k.com/sec-filings/report/884731/000119312516485544/d19643dex321.htm
  • Form Type: Annual
  • Number of times amended: 1
  • Accession Number: 0001193125-16-485544
  • Submitted to the SEC: Monday, February 29, 2016 4:52:31 PM EST
  • Accepted by the SEC: Monday, February 29, 2016
  • Fiscal Year ending: December 2015
  • Industry: Biological Products No Disgnostic Substances
Companies
 

ARIA

ARIAD PHARMACEUTICALS INC

Sponsored links


Health Reports:
Intrinsic Value, Financial Stability and Ratios

External Resources:

External link to SEC.gov Insider Transactions
External link to Bloomberg Stock Quote
External link to StockTwits.com Social Media